TRIM-EDICINE INC
Biotech · Private
Recombinant human MG53 (rhMG53), a tissue repair protein therapeutic formulated as a topical cream for chronic wound healing
trim-edicine.com →- Grants
- $6.0M
- 9 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 6
- 1 granted · 5 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Development of protein therapeutic for acute kidney injury | $833,693 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of protein therapeutic for acute kidney injury | $1,799,026 | |
| Federal grant | Department of Health and Human Services · Phase I · Protein therapeutic to facilitate healing of chronic wounds. | $262,198 | |
| Federal grant | Department of Health and Human Services · Phase I · Protein therapeutic to facilitate healing of chronic wounds | $262,198 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of protein therapeutic for acute kidney injury | $860,143 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of protein therapeutic for acute kidney injury | $105,190 | |
| Federal grant | Department of Health and Human Services · Phase II · Protein therapeutic to facilitate healing of chronic wounds. | $898,170 | |
| Federal grant | Department of Health and Human Services · Phase II · Protein therapeutic to facilitate healing of chronic wounds. | $948,478 | |
| Federal grant | Department of Health and Human Services · Phase II · Protein therapeutic to facilitate healing of chronic wounds. | $1 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2805 | Frontier Medicines | — | $122M |
| 2806 | Praxis Precision Medicine | — | — |
| 2807 | Seismic Therapeutic, Inc. | — | $121M |
| 2808 | TRIM-EDICINE INC | — | — |
| 2809 | Orna Therapeutics Holdings, LLC | — | $121M |
| 2810 | Edgewise Therapeutics | — | $120M |
| 2811 | Ensoma | — | $120M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Prevention and Treatment of Viral Infection and Viral Infection-Induced Organ Failuregranted
- Composition And Method Of Treating Hepatic Tissue Injuryapplication
- Cosmeceutical Compositionapplication
- Composition For And Method Of Improving Tissue Performanceapplication
- Composition For And Method Of Treating Hepatic Tissue Injuryapplication
- Composition For And Method Of Facilitating Corneal Tissue Repairapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.